HC Wainwright Issues Negative Estimate for Evommune Earnings

Evommune, Inc. (NYSE:EVMN) – Research analysts at HC Wainwright dropped their Q3 2026 earnings per share estimates for shares of Evommune in a report issued on Friday, August 7th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.91) per share for the quarter, down from their previous estimate of ($0.70). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Evommune’s current full-year earnings is ($2.83) per share. HC Wainwright also issued estimates for Evommune’s Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($3.41) EPS, Q1 2027 earnings at ($0.97) EPS, Q2 2027 earnings at ($1.01) EPS, Q3 2027 earnings at ($1.05) EPS, Q4 2027 earnings at ($1.11) EPS and FY2027 earnings at ($4.14) EPS.

Evommune (NYSE:EVMN) last announced its earnings results on Thursday, August 6th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.21).

A number of other equities research analysts have also weighed in on the company. Morgan Stanley dropped their price target on Evommune from $55.00 to $26.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 30th. Wall Street Zen lowered shares of Evommune from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Royal Bank Of Canada lowered their target price on shares of Evommune from $30.00 to $29.00 and set an “outperform” rating for the company in a research note on Friday. Stifel Nicolaus assumed coverage on shares of Evommune in a research report on Friday, May 1st. They set a “buy” rating and a $54.00 target price on the stock. Finally, William Blair lowered shares of Evommune from an “outperform” rating to a “market perform” rating in a research note on Monday, June 29th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $43.25.

Evommune Stock Performance

Evommune stock opened at $14.03 on Tuesday. The stock has a 50-day moving average of $15.84 and a two-hundred day moving average of $21.17. Evommune has a one year low of $10.47 and a one year high of $33.20. The stock has a market cap of $505.33 million and a PE ratio of -1.27.

Insider Transactions at Evommune

In related news, Director David E. Cohen sold 6,056 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $20.33, for a total value of $123,118.48. Following the transaction, the director owned 17,609 shares in the company, valued at approximately $357,990.97. This represents a 25.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jeegar Pravinkumar Patel sold 1,488 shares of Evommune stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $22.50, for a total transaction of $33,480.00. Following the sale, the insider owned 46,403 shares of the company’s stock, valued at approximately $1,044,067.50. The trade was a 3.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 100,854 shares of company stock valued at $2,279,142 over the last quarter. Company insiders own 31.10% of the company’s stock.

Hedge Funds Weigh In On Evommune

Institutional investors have recently modified their holdings of the stock. Strs Ohio acquired a new position in shares of Evommune in the 1st quarter valued at about $41,000. China Universal Asset Management Co. Ltd. purchased a new position in Evommune during the fourth quarter valued at approximately $34,000. The Manufacturers Life Insurance Company raised its position in Evommune by 25.3% during the first quarter. The Manufacturers Life Insurance Company now owns 12,812 shares of the company’s stock valued at $295,000 after acquiring an additional 2,587 shares in the last quarter. XTX Topco Ltd acquired a new position in Evommune in the fourth quarter valued at approximately $321,000. Finally, Oxford Asset Management LLP acquired a new position in Evommune in the fourth quarter valued at approximately $335,000.

Key Headlines Impacting Evommune

Here are the key news stories impacting Evommune this week:

• Negative Sentiment: HC Wainwright cut its FY2026 EPS forecast to a loss of $3.41 from $2.77 and reduced its FY2027 forecast to a loss of $4.14 from $3.33. The firm also lowered estimates for each reported quarter from Q3 2026 through Q4 2027, signaling expectations for deeper or more prolonged losses.
• Negative Sentiment: The quarterly estimate reductions were substantial: Q3 2026 EPS moved to a loss of $0.91 from $0.70, Q4 2026 to $0.94 from $0.74, Q1 2027 to $0.97 from $0.77, Q2 2027 to $1.01 from $0.82, Q3 2027 to $1.05 from $0.86, and Q4 2027 to $1.11 from $0.90. These changes point to weaker near-term earnings expectations.
• Negative Sentiment: Royal Bank of Canada lowered its price target for Evommune to $29, adding to the cautious analyst outlook. Royal Bank Of Canada Cuts Evommune Price Target

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.